These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


185 related items for PubMed ID: 14715838

  • 1. Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GH-releasing hormone drive.
    Veldhuis JD, Anderson SM, Patrie JT, Bowers CY.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):121-7. PubMed ID: 14715838
    [Abstract] [Full Text] [Related]

  • 2. Short-term estradiol replacement in postmenopausal women selectively mutes somatostatin's dose-dependent inhibition of fasting growth hormone secretion.
    Bray MJ, Vick TM, Shah N, Anderson SM, Rice LW, Iranmanesh A, Evans WS, Veldhuis JD.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3143-9. PubMed ID: 11443179
    [Abstract] [Full Text] [Related]

  • 3. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS, Anderson SM, Hull LT, Azimi PP, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [Abstract] [Full Text] [Related]

  • 4. Estradiol supplementation enhances submaximal feed-forward drive of growth hormone (GH) secretion by recombinant human GH-releasing hormone-1,44-amide in a putatively somatostatin-withdrawn milieu.
    Veldhuis JD, Evans WS, Bowers CY.
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5484-9. PubMed ID: 14602794
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
    Shah N, Evans WS, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Accelerated escape from GH autonegative feedback in midpuberty in males: evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys.
    Richmond E, Rogol AD, Basdemir D, Veldhuis OL, Clarke W, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3837-44. PubMed ID: 12161519
    [Abstract] [Full Text] [Related]

  • 12. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N, Evans WS, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp.
    Hudson SB, Schroeder DR, Bailey JN, Mielke KL, Erickson D, Miles JM, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2010 Jan; 95(1):353-60. PubMed ID: 19858315
    [Abstract] [Full Text] [Related]

  • 15. Contributions of gender and systemic estradiol and testosterone concentrations to maximal secretagogue drive of burst-like growth hormone secretion in healthy middle-aged and older adults.
    Veldhuis JD, Patrie JT, Brill KT, Weltman JY, Mueller EE, Bowers CY, Weltman A.
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6291-6. PubMed ID: 15579792
    [Abstract] [Full Text] [Related]

  • 16. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.
    Friend K, Iranmanesh A, Login IS, Veldhuis JD.
    Eur J Endocrinol; 1997 Oct; 137(4):377-86. PubMed ID: 9368506
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.